Bradmer Pharmaceuticals Inc. ("Bradmer" or the "Company") (TSX VENTURE:BMR.H)
today announced its fourth quarter and full year 2013 operational and financial
results.
Operational Highlights
On February 19, 2014, the Company announced that it had entered into a letter of
intent with Alpha Cancer Technologies Inc. ("Alpha") to complete a going-public
transaction for Alpha (the "Proposed Transaction"). Alpha is a pre-clinical
biopharmaceutical company with a targeted chemotherapy delivery platform focused
on the global oncology market. Alpha holds the exclusive worldwide rights to
recombinant human Alpha Fetoprotein (AFP), a shuttle protein that targets AFP
receptors found almost exclusively on most solid and liquid cancer cells.
In conjunction with, and prior to the closing of the Proposed Transaction, Alpha
intends to complete a private placement of Alpha Shares, 10% convertible notes,
subscription receipts and/or other securities convertible into Alpha Shares for
aggregate gross proceeds of between $7,000,000 and $10,000,000 (the "Private
Placement"), at an offering price or conversion price, as applicable, of $0.50
per Alpha Share. Euro Pacific Canada, Inc. has been engaged by Alpha to act as
agent for part of the Private Placement. Any convertible securities of Alpha
issued pursuant to the Private Placement will be converted to Alpha Shares
immediately prior to the completion of the Amalgamation with Bradmer. The
pricing of the Private Placement reflects a pre-money enterprise value for Alpha
of approximately $25,000,000.
For the purposes of the Proposed Transaction, the deemed value of each
outstanding Bradmer Share will be $0.0632 (on a pre-Amalgamation basis).
Financial Results
Amounts in US dollars, unless specified otherwise, and results prepared in
accordance with International Financial Reporting Standards ("IFRS").
For the year ended December 31, 2013, we recorded a net loss of $128,000 or
$0.007 per common share based on the weighted average outstanding shares of
19,659,726 during the year, compared to a net loss of $219,000 or $0.011 per
common share for the year ended December 31, 2012 based on the weighted average
outstanding shares of 19,659,726. The reduced loss in 2013 is attributable to
the $52,000 reduction in general and administrative expenses and the $29,000
foreign exchange gain in 2013 compared with the $10,000 foreign exchange loss in
2012.
General and administrative expenses were $157,000 in the year ended December 31,
2013 compared to $209,000 in the prior year.
Major expenses in 2013 consisted of consulting fees of $70,000, legal fees of
$26,000, insurance premiums of $19,000, audit fees of $17,000 and transfer agent
and stock exchange listing fees of $13,000. Major expenses in 2012 consisted of
consulting fees of $72,000, insurance premiums of $57,000, legal fees of
$30,000, audit fees of $20,000 and transfer agent and stock exchange listing
fees of $19,000. Limits on the directors' and officers' liability insurance were
reduced from $5,000,000 to $2,000,000 accounting for the substantial reduction
in premiums in 2013.
Fourth Quarter Results
The major reason for the decrease in the loss for the fourth quarter of 2013 to
$19,000 from the loss in the third quarter of 2013 of $47,000 was the foreign
exchange gain of $12,000 compared to the foreign exchange loss of $7,500 in the
previous quarter. General and administrative expenses also declined quarter over
quarter from $39,000 to $31,000.
Sources and Uses of Cash
Our operational activities for the year ended December 31, 2013 were financed by
cash on hand. At December 31, 2013, we had working capital of $785,000, compared
to $971,000 at December 31, 2012. We had available cash of $801,000 at December
31, 2013, compared to cash of $991,000 at December 31, 2012. The decrease was
primarily due to the $128,000 operating loss incurred in 2013 and the foreign
currency translation adjustments of $59,000.
As at March 7, 2014 and December 31, 2013, the Company had 19,659,726 common
shares and options to purchase 1,950,000 common shares outstanding.
Additional information about Bradmer, including the MD&A and financial results
may be found on SEDAR at www.sedar.com.
NEITHER THE TSX VENTURE EXCHANGE NOR ITS REGULATION PROVIDER (AS THAT TERM IS
DEFINED IN THE POLICIES OF THE TSX VENTURE EXCHANGE) ACCEPTS RESPONSIBILITY FOR
THE ADEQUACY OR ACCURACY OF THIS RELEASE.
Bradmer's common shares have not been registered under the Securities Act of
1933, as amended (the "Securities Act") or any state regulatory agency in the
United States. The resale or transfer by a U.S. investor of such common shares
of Bradmer Pharmaceuticals Inc. is subject to the requirements of Rule 904 of
Regulation S of the Securities Act or such other applicable exemption
thereunder, and other applicable state securities laws.
Except for historical information, this news release may contain forward-looking
statements, which reflect the Company's current expectation regarding future
events. These forward-looking statements involve risk and uncertainties, which
may cause but are not limited to, changing market conditions, the establishment
of corporate alliances, the impact of competitive products and pricing, new
product development, uncertainties related to the regulatory approval process
and other risks detailed from time to time in the Company's ongoing quarterly
and annual reporting.
BRADMER PHARMACEUTICALS INC.
Statements of Financial Position
As at December 31
(All amounts expressed in United States dollars)
----------------------------------------------------------------------------
----------------------------------------------------------------------------
2013 2012
----------------------------------------------------------------------------
Assets
Current assets
Cash $ 800,568 $ 990,759
Amounts receivable 6,668 2,861
Prepaid expenses 3,079 5,287
----------------------------------------------------------------------------
Total assets $ 810,315 $ 998,907
----------------------------------------------------------------------------
Liabilities and Shareholders' Equity
Current liabilities
Accounts payable and accrued liabilities $ 25,665 $ 27,440
----------------------------------------------------------------------------
Shareholders' Equity
Share capital 2,158,896 2,307,972
Contributed surplus 2,385,647 2,550,381
Accumulated other comprehensive income/(loss) 98,604 (156,515)
Deficit (3,858,497) (3,730,371)
----------------------------------------------------------------------------
Total shareholders' equity 784,650 971,467
----------------------------------------------------------------------------
Total liabilities and shareholders' equity $ 810,315 $ 998,907
BRADMER PHARMACEUTICALS INC.
Statements of Comprehensive Income/(Loss)
For the years ended December 31, 2013 and 2012
(All amounts expressed in United States dollars)
----------------------------------------------------------------------------
----------------------------------------------------------------------------
2013 2012
----------------------------------------------------------------------------
Expenses
General and administrative $ 157,163 $ 209,375
----------------------------------------------------------------------------
Other Income
Interest (203) (390)
Foreign exchange (gain)/loss (28,834) 9,765
----------------------------------------------------------------------------
(29,037) 9,375
----------------------------------------------------------------------------
Loss for the year $ (128,126) $ (218,750)
Other comprehensive income/(loss) 255,119 (80,717)
----------------------------------------------------------------------------
Comprehensive income/(loss) for the year $ 126,993 $ (299,467)
----------------------------------------------------------------------------
----------------------------------------------------------------------------
Loss per share
Basic and diluted $ (0.007) $ (0.011)
----------------------------------------------------------------------------
Weighted average number of shares outstanding 19,659,726 19,659,726
----------------------------------------------------------------------------
BRADMER PHARMACEUTICALS INC.
Statements of Changes in Shareholders' Equity
For the years ended December 31, 2013 and 2012
(All amounts expressed in United States dollars)
----------------------------------------------------------------------------
----------------------------------------------------------------------------
Share capital
Number Contributed
of shares Amount Warrants surplus
----------------------------------------------------------------------------
Balance, January
1, 2012 19,659,726 $ 2,257,819 $ 23,255 $ 2,471,705
Expiry of
warrants - - (23,255) 23,255
Foreign currency
translation
adjustment - 50,153 - 55,421
Loss for the year - - - -
----------------------------------------------------------------------------
Balance, December
31, 2012 19,659,726 $ 2,307,972 $ - $ 2,550,381
Foreign currency
translation
adjustment - (149,076) - (164,734)
Loss for the year - - - -
----------------------------------------------------------------------------
Balance, December
31, 2013 19,659,726 $ 2,158,896 $ - $ 2,385,647
----------------------------------------------------------------------------
----------------------------------------------------------------------------
Accumulated
Other Total
Comprehensive Shareholders'
Income/ (Loss) Deficit equity
--------------------------------------------------------------
Balance, January
1, 2012 $ (75,798) $ (3,511,621) $ 1,165,360
Expiry of
warrants - - -
Foreign currency
translation
adjustment (80,717) - 24,857
Loss for the year - (218,750) (218,750)
--------------------------------------------------------------
Balance, December
31, 2012 $ (156,515) $ (3,730,371) $ 971,467
Foreign currency
translation
adjustment 255,119 - (58,691)
Loss for the year - (128,126) (128,126)
--------------------------------------------------------------
Balance, December
31, 2013 $ 98,604 $ (3,858,497) $ 784,650
--------------------------------------------------------------
--------------------------------------------------------------
BRADMER PHARMACEUTICALS INC.
Statements of Cash Flows
For the years ended December 31, 2013 and 2012
(All amounts expressed in United States dollars)
----------------------------------------------------------------------------
----------------------------------------------------------------------------
2013 2012
----------------------------------------------------------------------------
Cash flows from operating activities
Loss for the year $ (128,126) $ (218,750)
Adjustments for:
Foreign currency translation adjustment (58,691) 24,857
----------------------------------------------------------------------------
(186,817) (193,893)
Change in non-cash operating items
Amounts receivable (3,807) 90
Prepaid expenses 2,208 2,266
Accounts payable and accrued expenses (1,775) (10,011)
----------------------------------------------------------------------------
Decrease in cash (190,191) (201,548)
Cash at beginning of year 990,759 1,192,307
----------------------------------------------------------------------------
Cash at end of year $ 800,568 $ 990,759
----------------------------------------------------------------------------
FOR FURTHER INFORMATION PLEASE CONTACT:
Bradmer Pharmaceuticals Inc.
Paul Van Damme
Chief Financial Officer
1.416.847.6905
pvandamme@bradmerpharma.com
Bradmer Pharmaceuticals (TSXV:BMR.H)
Historical Stock Chart
From May 2024 to Jun 2024
Bradmer Pharmaceuticals (TSXV:BMR.H)
Historical Stock Chart
From Jun 2023 to Jun 2024
